nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfuzosin—CYP3A4—type 2 diabetes mellitus	0.242	1	CbGaD
Alfuzosin—ADRA1D—Bromocriptine—type 2 diabetes mellitus	0.111	0.239	CbGbCtD
Alfuzosin—ADRA1B—Bromocriptine—type 2 diabetes mellitus	0.0808	0.174	CbGbCtD
Alfuzosin—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0638	0.137	CbGbCtD
Alfuzosin—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0318	0.0685	CbGbCtD
Alfuzosin—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0283	0.061	CbGbCtD
Alfuzosin—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0259	0.0558	CbGbCtD
Alfuzosin—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0226	0.0488	CbGbCtD
Alfuzosin—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0205	0.0441	CbGbCtD
Alfuzosin—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0155	0.0334	CbGbCtD
Alfuzosin—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0149	0.032	CbGbCtD
Alfuzosin—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0149	0.032	CbGbCtD
Alfuzosin—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0141	0.0303	CbGbCtD
Alfuzosin—CYP3A4—Glyburide—type 2 diabetes mellitus	0.0105	0.0226	CbGbCtD
Alfuzosin—CYP3A4—Losartan—type 2 diabetes mellitus	0.00959	0.0207	CbGbCtD
Alfuzosin—Doxazosin—ADRA2A—type 2 diabetes mellitus	0.00106	0.521	CrCbGaD
Alfuzosin—Prazosin—ADRA2A—type 2 diabetes mellitus	0.000979	0.48	CrCbGaD
Alfuzosin—Palpitations—Metformin—type 2 diabetes mellitus	0.000169	0.000796	CcSEcCtD
Alfuzosin—Shock—Valsartan—type 2 diabetes mellitus	0.000169	0.000794	CcSEcCtD
Alfuzosin—Infection—Orlistat—type 2 diabetes mellitus	0.000168	0.000793	CcSEcCtD
Alfuzosin—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.000168	0.000792	CcSEcCtD
Alfuzosin—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000168	0.000792	CcSEcCtD
Alfuzosin—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	0.000168	0.000791	CcSEcCtD
Alfuzosin—Ill-defined disorder—Irbesartan—type 2 diabetes mellitus	0.000167	0.000789	CcSEcCtD
Alfuzosin—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000167	0.000785	CcSEcCtD
Alfuzosin—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000166	0.000784	CcSEcCtD
Alfuzosin—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000166	0.000782	CcSEcCtD
Alfuzosin—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000166	0.000782	CcSEcCtD
Alfuzosin—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000166	0.000781	CcSEcCtD
Alfuzosin—Urticaria—Glyburide—type 2 diabetes mellitus	0.000165	0.000778	CcSEcCtD
Alfuzosin—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000165	0.000777	CcSEcCtD
Alfuzosin—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000164	0.000775	CcSEcCtD
Alfuzosin—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.000164	0.000775	CcSEcCtD
Alfuzosin—Back pain—Losartan—type 2 diabetes mellitus	0.000164	0.000774	CcSEcCtD
Alfuzosin—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000164	0.000774	CcSEcCtD
Alfuzosin—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000164	0.000774	CcSEcCtD
Alfuzosin—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.000164	0.000771	CcSEcCtD
Alfuzosin—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000163	0.000768	CcSEcCtD
Alfuzosin—Chest pain—Metformin—type 2 diabetes mellitus	0.000163	0.000767	CcSEcCtD
Alfuzosin—Malaise—Irbesartan—type 2 diabetes mellitus	0.000163	0.000767	CcSEcCtD
Alfuzosin—Vertigo—Irbesartan—type 2 diabetes mellitus	0.000162	0.000764	CcSEcCtD
Alfuzosin—Headache—Pioglitazone—type 2 diabetes mellitus	0.000162	0.000763	CcSEcCtD
Alfuzosin—Syncope—Irbesartan—type 2 diabetes mellitus	0.000162	0.000762	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000162	0.000762	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000161	0.000759	CcSEcCtD
Alfuzosin—Discomfort—Metformin—type 2 diabetes mellitus	0.000161	0.000758	CcSEcCtD
Alfuzosin—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000161	0.000758	CcSEcCtD
Alfuzosin—Nausea—Glipizide—type 2 diabetes mellitus	0.00016	0.000755	CcSEcCtD
Alfuzosin—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00016	0.000755	CcSEcCtD
Alfuzosin—Hypotension—Valsartan—type 2 diabetes mellitus	0.00016	0.000755	CcSEcCtD
Alfuzosin—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.00016	0.000752	CcSEcCtD
Alfuzosin—Pain—Gliclazide—type 2 diabetes mellitus	0.000159	0.000752	CcSEcCtD
Alfuzosin—Constipation—Gliclazide—type 2 diabetes mellitus	0.000159	0.000752	CcSEcCtD
Alfuzosin—Rash—Glimepiride—type 2 diabetes mellitus	0.000159	0.000748	CcSEcCtD
Alfuzosin—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000159	0.000748	CcSEcCtD
Alfuzosin—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.000159	0.000747	CcSEcCtD
Alfuzosin—Rash—Sitagliptin—type 2 diabetes mellitus	0.000158	0.000746	CcSEcCtD
Alfuzosin—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000158	0.000745	CcSEcCtD
Alfuzosin—Headache—Glimepiride—type 2 diabetes mellitus	0.000158	0.000743	CcSEcCtD
Alfuzosin—Ill-defined disorder—Losartan—type 2 diabetes mellitus	0.000158	0.000742	CcSEcCtD
Alfuzosin—Headache—Sitagliptin—type 2 diabetes mellitus	0.000157	0.000741	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000156	0.000736	CcSEcCtD
Alfuzosin—Oedema—Metformin—type 2 diabetes mellitus	0.000156	0.000735	CcSEcCtD
Alfuzosin—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000155	0.000733	CcSEcCtD
Alfuzosin—Flushing—Ramipril—type 2 diabetes mellitus	0.000155	0.000731	CcSEcCtD
Alfuzosin—Angioedema—Losartan—type 2 diabetes mellitus	0.000155	0.000731	CcSEcCtD
Alfuzosin—Infection—Metformin—type 2 diabetes mellitus	0.000155	0.000731	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000154	0.000727	CcSEcCtD
Alfuzosin—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000154	0.000724	CcSEcCtD
Alfuzosin—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000154	0.000724	CcSEcCtD
Alfuzosin—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000154	0.000724	CcSEcCtD
Alfuzosin—Shock—Metformin—type 2 diabetes mellitus	0.000154	0.000723	CcSEcCtD
Alfuzosin—Malaise—Losartan—type 2 diabetes mellitus	0.000153	0.000722	CcSEcCtD
Alfuzosin—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000153	0.000721	CcSEcCtD
Alfuzosin—Thrombocytopenia—Metformin—type 2 diabetes mellitus	0.000153	0.00072	CcSEcCtD
Alfuzosin—Vertigo—Losartan—type 2 diabetes mellitus	0.000153	0.000719	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000153	0.000719	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000152	0.000719	CcSEcCtD
Alfuzosin—Somnolence—Valsartan—type 2 diabetes mellitus	0.000152	0.000718	CcSEcCtD
Alfuzosin—Syncope—Losartan—type 2 diabetes mellitus	0.000152	0.000718	CcSEcCtD
Alfuzosin—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000152	0.000715	CcSEcCtD
Alfuzosin—Skin disorder—Metformin—type 2 diabetes mellitus	0.000152	0.000714	CcSEcCtD
Alfuzosin—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000151	0.000711	CcSEcCtD
Alfuzosin—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000151	0.000711	CcSEcCtD
Alfuzosin—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000151	0.00071	CcSEcCtD
Alfuzosin—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.00015	0.000708	CcSEcCtD
Alfuzosin—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.00015	0.000708	CcSEcCtD
Alfuzosin—Palpitations—Losartan—type 2 diabetes mellitus	0.00015	0.000707	CcSEcCtD
Alfuzosin—Nausea—Glimepiride—type 2 diabetes mellitus	0.00015	0.000705	CcSEcCtD
Alfuzosin—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000149	0.000703	CcSEcCtD
Alfuzosin—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000149	0.000703	CcSEcCtD
Alfuzosin—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000149	0.000702	CcSEcCtD
Alfuzosin—Asthenia—Glyburide—type 2 diabetes mellitus	0.000149	0.000702	CcSEcCtD
Alfuzosin—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000148	0.000698	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000148	0.000697	CcSEcCtD
Alfuzosin—Fatigue—Valsartan—type 2 diabetes mellitus	0.000148	0.000696	CcSEcCtD
Alfuzosin—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000147	0.000695	CcSEcCtD
Alfuzosin—Oedema—Irbesartan—type 2 diabetes mellitus	0.000147	0.000694	CcSEcCtD
Alfuzosin—Pruritus—Glyburide—type 2 diabetes mellitus	0.000147	0.000692	CcSEcCtD
Alfuzosin—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000147	0.000691	CcSEcCtD
Alfuzosin—Constipation—Valsartan—type 2 diabetes mellitus	0.000147	0.000691	CcSEcCtD
Alfuzosin—Infection—Irbesartan—type 2 diabetes mellitus	0.000146	0.000689	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000146	0.000689	CcSEcCtD
Alfuzosin—Fatigue—Orlistat—type 2 diabetes mellitus	0.000146	0.000688	CcSEcCtD
Alfuzosin—Hypotension—Metformin—type 2 diabetes mellitus	0.000146	0.000687	CcSEcCtD
Alfuzosin—Shock—Irbesartan—type 2 diabetes mellitus	0.000145	0.000683	CcSEcCtD
Alfuzosin—Pain—Orlistat—type 2 diabetes mellitus	0.000145	0.000682	CcSEcCtD
Alfuzosin—Arthralgia—Losartan—type 2 diabetes mellitus	0.000145	0.000681	CcSEcCtD
Alfuzosin—Chest pain—Losartan—type 2 diabetes mellitus	0.000145	0.000681	CcSEcCtD
Alfuzosin—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000144	0.000681	CcSEcCtD
Alfuzosin—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000144	0.000681	CcSEcCtD
Alfuzosin—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	0.000144	0.000679	CcSEcCtD
Alfuzosin—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000144	0.000677	CcSEcCtD
Alfuzosin—Rash—Bromocriptine—type 2 diabetes mellitus	0.000143	0.000675	CcSEcCtD
Alfuzosin—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000143	0.000674	CcSEcCtD
Alfuzosin—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000143	0.000674	CcSEcCtD
Alfuzosin—Discomfort—Losartan—type 2 diabetes mellitus	0.000143	0.000673	CcSEcCtD
Alfuzosin—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000142	0.000671	CcSEcCtD
Alfuzosin—Headache—Bromocriptine—type 2 diabetes mellitus	0.000142	0.000671	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000142	0.00067	CcSEcCtD
Alfuzosin—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000142	0.00067	CcSEcCtD
Alfuzosin—Dry mouth—Losartan—type 2 diabetes mellitus	0.000141	0.000666	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.00014	0.00066	CcSEcCtD
Alfuzosin—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.00014	0.000658	CcSEcCtD
Alfuzosin—Somnolence—Metformin—type 2 diabetes mellitus	0.000139	0.000654	CcSEcCtD
Alfuzosin—Oedema—Losartan—type 2 diabetes mellitus	0.000139	0.000653	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000138	0.000652	CcSEcCtD
Alfuzosin—Infection—Losartan—type 2 diabetes mellitus	0.000138	0.000649	CcSEcCtD
Alfuzosin—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000138	0.000648	CcSEcCtD
Alfuzosin—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000137	0.000647	CcSEcCtD
Alfuzosin—Shock—Losartan—type 2 diabetes mellitus	0.000136	0.000642	CcSEcCtD
Alfuzosin—Urticaria—Valsartan—type 2 diabetes mellitus	0.000136	0.000641	CcSEcCtD
Alfuzosin—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000136	0.00064	CcSEcCtD
Alfuzosin—Thrombocytopenia—Losartan—type 2 diabetes mellitus	0.000136	0.000639	CcSEcCtD
Alfuzosin—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000135	0.000638	CcSEcCtD
Alfuzosin—Tachycardia—Losartan—type 2 diabetes mellitus	0.000135	0.000637	CcSEcCtD
Alfuzosin—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	0.000135	0.000637	CcSEcCtD
Alfuzosin—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000135	0.000636	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000135	0.000635	CcSEcCtD
Alfuzosin—Fatigue—Metformin—type 2 diabetes mellitus	0.000135	0.000634	CcSEcCtD
Alfuzosin—Urticaria—Orlistat—type 2 diabetes mellitus	0.000134	0.000634	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000134	0.000632	CcSEcCtD
Alfuzosin—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000134	0.000631	CcSEcCtD
Alfuzosin—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000134	0.000631	CcSEcCtD
Alfuzosin—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000134	0.000631	CcSEcCtD
Alfuzosin—Constipation—Metformin—type 2 diabetes mellitus	0.000133	0.000629	CcSEcCtD
Alfuzosin—Angioedema—Ramipril—type 2 diabetes mellitus	0.000133	0.000627	CcSEcCtD
Alfuzosin—Vomiting—Glyburide—type 2 diabetes mellitus	0.000132	0.000622	CcSEcCtD
Alfuzosin—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000132	0.000622	CcSEcCtD
Alfuzosin—Malaise—Ramipril—type 2 diabetes mellitus	0.000131	0.000619	CcSEcCtD
Alfuzosin—Rash—Glyburide—type 2 diabetes mellitus	0.000131	0.000617	CcSEcCtD
Alfuzosin—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000131	0.000617	CcSEcCtD
Alfuzosin—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000131	0.000617	CcSEcCtD
Alfuzosin—Vertigo—Ramipril—type 2 diabetes mellitus	0.000131	0.000616	CcSEcCtD
Alfuzosin—Syncope—Ramipril—type 2 diabetes mellitus	0.000131	0.000615	CcSEcCtD
Alfuzosin—Headache—Glyburide—type 2 diabetes mellitus	0.00013	0.000613	CcSEcCtD
Alfuzosin—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.00013	0.000611	CcSEcCtD
Alfuzosin—Hypotension—Losartan—type 2 diabetes mellitus	0.000129	0.00061	CcSEcCtD
Alfuzosin—Palpitations—Ramipril—type 2 diabetes mellitus	0.000129	0.000606	CcSEcCtD
Alfuzosin—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000129	0.000606	CcSEcCtD
Alfuzosin—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000128	0.000603	CcSEcCtD
Alfuzosin—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000128	0.000601	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000128	0.000601	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000127	0.000599	CcSEcCtD
Alfuzosin—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000127	0.000598	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000126	0.000595	CcSEcCtD
Alfuzosin—Pain—Irbesartan—type 2 diabetes mellitus	0.000126	0.000593	CcSEcCtD
Alfuzosin—Constipation—Irbesartan—type 2 diabetes mellitus	0.000126	0.000593	CcSEcCtD
Alfuzosin—Urticaria—Metformin—type 2 diabetes mellitus	0.000124	0.000584	CcSEcCtD
Alfuzosin—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000124	0.000584	CcSEcCtD
Alfuzosin—Chest pain—Ramipril—type 2 diabetes mellitus	0.000124	0.000584	CcSEcCtD
Alfuzosin—Nausea—Glyburide—type 2 diabetes mellitus	0.000123	0.000581	CcSEcCtD
Alfuzosin—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000123	0.000581	CcSEcCtD
Alfuzosin—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000123	0.000581	CcSEcCtD
Alfuzosin—Somnolence—Losartan—type 2 diabetes mellitus	0.000123	0.000581	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000123	0.00058	CcSEcCtD
Alfuzosin—Asthenia—Valsartan—type 2 diabetes mellitus	0.000123	0.000579	CcSEcCtD
Alfuzosin—Discomfort—Ramipril—type 2 diabetes mellitus	0.000122	0.000577	CcSEcCtD
Alfuzosin—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000122	0.000575	CcSEcCtD
Alfuzosin—Asthenia—Orlistat—type 2 diabetes mellitus	0.000121	0.000572	CcSEcCtD
Alfuzosin—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000121	0.000572	CcSEcCtD
Alfuzosin—Pruritus—Valsartan—type 2 diabetes mellitus	0.000121	0.000571	CcSEcCtD
Alfuzosin—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000121	0.000571	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.00012	0.000567	CcSEcCtD
Alfuzosin—Pruritus—Orlistat—type 2 diabetes mellitus	0.00012	0.000565	CcSEcCtD
Alfuzosin—Fatigue—Losartan—type 2 diabetes mellitus	0.000119	0.000563	CcSEcCtD
Alfuzosin—Oedema—Ramipril—type 2 diabetes mellitus	0.000119	0.00056	CcSEcCtD
Alfuzosin—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000119	0.000559	CcSEcCtD
Alfuzosin—Pain—Losartan—type 2 diabetes mellitus	0.000118	0.000558	CcSEcCtD
Alfuzosin—Constipation—Losartan—type 2 diabetes mellitus	0.000118	0.000558	CcSEcCtD
Alfuzosin—Rash—Gliclazide—type 2 diabetes mellitus	0.000118	0.000554	CcSEcCtD
Alfuzosin—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000117	0.000554	CcSEcCtD
Alfuzosin—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000117	0.000552	CcSEcCtD
Alfuzosin—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000117	0.000551	CcSEcCtD
Alfuzosin—Shock—Ramipril—type 2 diabetes mellitus	0.000117	0.000551	CcSEcCtD
Alfuzosin—Headache—Gliclazide—type 2 diabetes mellitus	0.000117	0.000551	CcSEcCtD
Alfuzosin—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000117	0.000549	CcSEcCtD
Alfuzosin—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000116	0.000549	CcSEcCtD
Alfuzosin—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	0.000116	0.000548	CcSEcCtD
Alfuzosin—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000116	0.000547	CcSEcCtD
Alfuzosin—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000116	0.000546	CcSEcCtD
Alfuzosin—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000115	0.000544	CcSEcCtD
Alfuzosin—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000115	0.000541	CcSEcCtD
Alfuzosin—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000114	0.000538	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000113	0.000534	CcSEcCtD
Alfuzosin—Dizziness—Valsartan—type 2 diabetes mellitus	0.000113	0.000534	CcSEcCtD
Alfuzosin—Dizziness—Orlistat—type 2 diabetes mellitus	0.000112	0.000528	CcSEcCtD
Alfuzosin—Asthenia—Metformin—type 2 diabetes mellitus	0.000112	0.000528	CcSEcCtD
Alfuzosin—Hypotension—Ramipril—type 2 diabetes mellitus	0.000111	0.000523	CcSEcCtD
Alfuzosin—Nausea—Gliclazide—type 2 diabetes mellitus	0.000111	0.000522	CcSEcCtD
Alfuzosin—Pruritus—Metformin—type 2 diabetes mellitus	0.00011	0.00052	CcSEcCtD
Alfuzosin—Urticaria—Losartan—type 2 diabetes mellitus	0.00011	0.000519	CcSEcCtD
Alfuzosin—Abdominal pain—Losartan—type 2 diabetes mellitus	0.00011	0.000516	CcSEcCtD
Alfuzosin—Vomiting—Valsartan—type 2 diabetes mellitus	0.000109	0.000513	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000108	0.00051	CcSEcCtD
Alfuzosin—Rash—Valsartan—type 2 diabetes mellitus	0.000108	0.000509	CcSEcCtD
Alfuzosin—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000108	0.000509	CcSEcCtD
Alfuzosin—Vomiting—Orlistat—type 2 diabetes mellitus	0.000108	0.000507	CcSEcCtD
Alfuzosin—Headache—Valsartan—type 2 diabetes mellitus	0.000107	0.000506	CcSEcCtD
Alfuzosin—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000107	0.000503	CcSEcCtD
Alfuzosin—Rash—Orlistat—type 2 diabetes mellitus	0.000107	0.000503	CcSEcCtD
Alfuzosin—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000107	0.000503	CcSEcCtD
Alfuzosin—Headache—Orlistat—type 2 diabetes mellitus	0.000106	0.0005	CcSEcCtD
Alfuzosin—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000106	0.000498	CcSEcCtD
Alfuzosin—Somnolence—Ramipril—type 2 diabetes mellitus	0.000106	0.000498	CcSEcCtD
Alfuzosin—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000105	0.000493	CcSEcCtD
Alfuzosin—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000104	0.000491	CcSEcCtD
Alfuzosin—Dizziness—Metformin—type 2 diabetes mellitus	0.000103	0.000486	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000103	0.000483	CcSEcCtD
Alfuzosin—Fatigue—Ramipril—type 2 diabetes mellitus	0.000102	0.000483	CcSEcCtD
Alfuzosin—Nausea—Valsartan—type 2 diabetes mellitus	0.000102	0.00048	CcSEcCtD
Alfuzosin—Constipation—Ramipril—type 2 diabetes mellitus	0.000102	0.000479	CcSEcCtD
Alfuzosin—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000101	0.000475	CcSEcCtD
Alfuzosin—Nausea—Orlistat—type 2 diabetes mellitus	0.000101	0.000474	CcSEcCtD
Alfuzosin—Asthenia—Losartan—type 2 diabetes mellitus	9.94e-05	0.000469	CcSEcCtD
Alfuzosin—Vomiting—Metformin—type 2 diabetes mellitus	9.92e-05	0.000468	CcSEcCtD
Alfuzosin—Rash—Metformin—type 2 diabetes mellitus	9.84e-05	0.000464	CcSEcCtD
Alfuzosin—Dermatitis—Metformin—type 2 diabetes mellitus	9.83e-05	0.000463	CcSEcCtD
Alfuzosin—Pruritus—Losartan—type 2 diabetes mellitus	9.8e-05	0.000462	CcSEcCtD
Alfuzosin—Feeling abnormal—Ramipril—type 2 diabetes mellitus	9.79e-05	0.000461	CcSEcCtD
Alfuzosin—Headache—Metformin—type 2 diabetes mellitus	9.77e-05	0.000461	CcSEcCtD
Alfuzosin—Dizziness—Irbesartan—type 2 diabetes mellitus	9.74e-05	0.000459	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	9.72e-05	0.000458	CcSEcCtD
Alfuzosin—Diarrhoea—Losartan—type 2 diabetes mellitus	9.48e-05	0.000447	CcSEcCtD
Alfuzosin—Urticaria—Ramipril—type 2 diabetes mellitus	9.44e-05	0.000445	CcSEcCtD
Alfuzosin—Abdominal pain—Ramipril—type 2 diabetes mellitus	9.39e-05	0.000443	CcSEcCtD
Alfuzosin—Vomiting—Irbesartan—type 2 diabetes mellitus	9.36e-05	0.000441	CcSEcCtD
Alfuzosin—Rash—Irbesartan—type 2 diabetes mellitus	9.28e-05	0.000438	CcSEcCtD
Alfuzosin—Dermatitis—Irbesartan—type 2 diabetes mellitus	9.28e-05	0.000437	CcSEcCtD
Alfuzosin—Nausea—Metformin—type 2 diabetes mellitus	9.27e-05	0.000437	CcSEcCtD
Alfuzosin—Headache—Irbesartan—type 2 diabetes mellitus	9.22e-05	0.000435	CcSEcCtD
Alfuzosin—Dizziness—Losartan—type 2 diabetes mellitus	9.16e-05	0.000432	CcSEcCtD
Alfuzosin—Vomiting—Losartan—type 2 diabetes mellitus	8.81e-05	0.000415	CcSEcCtD
Alfuzosin—Nausea—Irbesartan—type 2 diabetes mellitus	8.75e-05	0.000412	CcSEcCtD
Alfuzosin—Rash—Losartan—type 2 diabetes mellitus	8.74e-05	0.000412	CcSEcCtD
Alfuzosin—Dermatitis—Losartan—type 2 diabetes mellitus	8.73e-05	0.000411	CcSEcCtD
Alfuzosin—Headache—Losartan—type 2 diabetes mellitus	8.68e-05	0.000409	CcSEcCtD
Alfuzosin—Asthenia—Ramipril—type 2 diabetes mellitus	8.52e-05	0.000402	CcSEcCtD
Alfuzosin—Pruritus—Ramipril—type 2 diabetes mellitus	8.41e-05	0.000396	CcSEcCtD
Alfuzosin—Nausea—Losartan—type 2 diabetes mellitus	8.23e-05	0.000388	CcSEcCtD
Alfuzosin—Diarrhoea—Ramipril—type 2 diabetes mellitus	8.13e-05	0.000383	CcSEcCtD
Alfuzosin—Dizziness—Ramipril—type 2 diabetes mellitus	7.86e-05	0.00037	CcSEcCtD
Alfuzosin—Vomiting—Ramipril—type 2 diabetes mellitus	7.55e-05	0.000356	CcSEcCtD
Alfuzosin—Rash—Ramipril—type 2 diabetes mellitus	7.49e-05	0.000353	CcSEcCtD
Alfuzosin—Dermatitis—Ramipril—type 2 diabetes mellitus	7.48e-05	0.000353	CcSEcCtD
Alfuzosin—Headache—Ramipril—type 2 diabetes mellitus	7.44e-05	0.000351	CcSEcCtD
Alfuzosin—Nausea—Ramipril—type 2 diabetes mellitus	7.06e-05	0.000333	CcSEcCtD
Alfuzosin—ADRA1D—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.36e-05	0.000171	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—AGTR2—type 2 diabetes mellitus	1.36e-05	0.00017	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.35e-05	0.000169	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	1.35e-05	0.000169	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	1.35e-05	0.000169	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.35e-05	0.000169	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.35e-05	0.000169	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CCR5—type 2 diabetes mellitus	1.34e-05	0.000168	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.33e-05	0.000167	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—C3—type 2 diabetes mellitus	1.31e-05	0.000164	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	1.3e-05	0.000163	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	1.3e-05	0.000163	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	1.3e-05	0.000163	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	1.3e-05	0.000163	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	1.3e-05	0.000163	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EDNRB—type 2 diabetes mellitus	1.3e-05	0.000163	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.29e-05	0.000162	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.29e-05	0.000162	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.28e-05	0.00016	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	1.27e-05	0.000158	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.26e-05	0.000158	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—AVP—type 2 diabetes mellitus	1.26e-05	0.000158	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.26e-05	0.000158	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.26e-05	0.000158	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	1.26e-05	0.000158	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.26e-05	0.000157	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.25e-05	0.000157	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.25e-05	0.000157	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.25e-05	0.000156	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—AGT—type 2 diabetes mellitus	1.24e-05	0.000156	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.24e-05	0.000155	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—GCG—type 2 diabetes mellitus	1.23e-05	0.000154	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.23e-05	0.000154	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.23e-05	0.000154	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.22e-05	0.000153	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.22e-05	0.000153	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—APOB—type 2 diabetes mellitus	1.22e-05	0.000153	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.21e-05	0.000152	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.21e-05	0.000152	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.21e-05	0.000151	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.2e-05	0.00015	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.2e-05	0.00015	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.2e-05	0.00015	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.2e-05	0.00015	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	1.19e-05	0.000149	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	1.19e-05	0.000149	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.18e-05	0.000148	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—LPL—type 2 diabetes mellitus	1.16e-05	0.000146	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	1.16e-05	0.000145	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.15e-05	0.000144	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.15e-05	0.000144	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.14e-05	0.000143	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.13e-05	0.000142	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.13e-05	0.000142	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.11e-05	0.000139	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.11e-05	0.000139	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	1.11e-05	0.000139	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	1.11e-05	0.000139	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	1.11e-05	0.000139	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—GCG—type 2 diabetes mellitus	1.09e-05	0.000137	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.09e-05	0.000137	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.09e-05	0.000137	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.08e-05	0.000135	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.07e-05	0.000134	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.07e-05	0.000134	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.07e-05	0.000134	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.06e-05	0.000133	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	1.06e-05	0.000133	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	1.06e-05	0.000133	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—C3—type 2 diabetes mellitus	1.05e-05	0.000131	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—AVP—type 2 diabetes mellitus	1.05e-05	0.000131	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.05e-05	0.000131	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.04e-05	0.000131	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.04e-05	0.00013	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.03e-05	0.000129	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.02e-05	0.000128	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	1.02e-05	0.000128	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	1.02e-05	0.000128	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—APOB—type 2 diabetes mellitus	1.01e-05	0.000127	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.01e-05	0.000126	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.01e-05	0.000126	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.01e-05	0.000126	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	1e-05	0.000126	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1e-05	0.000125	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IRS2—type 2 diabetes mellitus	9.98e-06	0.000125	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—AGT—type 2 diabetes mellitus	9.97e-06	0.000125	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.96e-06	0.000125	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	9.86e-06	0.000123	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	9.86e-06	0.000123	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	9.86e-06	0.000123	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CALM1—type 2 diabetes mellitus	9.8e-06	0.000123	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—APOE—type 2 diabetes mellitus	9.76e-06	0.000122	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—LEP—type 2 diabetes mellitus	9.76e-06	0.000122	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—LPL—type 2 diabetes mellitus	9.67e-06	0.000121	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—APOA1—type 2 diabetes mellitus	9.65e-06	0.000121	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	9.52e-06	0.000119	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.46e-06	0.000119	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—GNB3—type 2 diabetes mellitus	9.43e-06	0.000118	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—AVP—type 2 diabetes mellitus	9.31e-06	0.000117	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MMP3—type 2 diabetes mellitus	9.31e-06	0.000117	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	9.27e-06	0.000116	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IGF2—type 2 diabetes mellitus	9.26e-06	0.000116	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	9.22e-06	0.000115	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PRKCB—type 2 diabetes mellitus	9.21e-06	0.000115	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	9.13e-06	0.000114	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	9.07e-06	0.000114	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—APOB—type 2 diabetes mellitus	8.99e-06	0.000113	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	8.96e-06	0.000112	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.91e-06	0.000112	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EDN1—type 2 diabetes mellitus	8.85e-06	0.000111	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IRS1—type 2 diabetes mellitus	8.71e-06	0.000109	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—C3—type 2 diabetes mellitus	8.7e-06	0.000109	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	8.68e-06	0.000109	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—LPL—type 2 diabetes mellitus	8.59e-06	0.000108	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.41e-06	0.000105	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	8.39e-06	0.000105	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	8.39e-06	0.000105	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	8.39e-06	0.000105	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	8.39e-06	0.000105	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—INS—type 2 diabetes mellitus	8.34e-06	0.000104	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	8.3e-06	0.000104	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IRS2—type 2 diabetes mellitus	8.28e-06	0.000104	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—AGT—type 2 diabetes mellitus	8.27e-06	0.000104	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CCL2—type 2 diabetes mellitus	8.21e-06	0.000103	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.13e-06	0.000102	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—LEP—type 2 diabetes mellitus	8.1e-06	0.000101	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—APOE—type 2 diabetes mellitus	8.1e-06	0.000101	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IGF1—type 2 diabetes mellitus	8.07e-06	0.000101	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—AKT2—type 2 diabetes mellitus	8.06e-06	0.000101	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.06e-06	0.000101	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	8.04e-06	0.000101	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—EGFR—type 2 diabetes mellitus	8.03e-06	0.000101	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—APOA1—type 2 diabetes mellitus	8.01e-06	0.0001	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	7.91e-06	9.91e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—C3—type 2 diabetes mellitus	7.73e-06	9.68e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.66e-06	9.59e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.64e-06	9.57e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	7.47e-06	9.36e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.37e-06	9.23e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.36e-06	9.21e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—AGT—type 2 diabetes mellitus	7.35e-06	9.2e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	7.31e-06	9.16e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—NOS3—type 2 diabetes mellitus	7.31e-06	9.16e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.23e-06	9.05e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.22e-06	9.04e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—APOE—type 2 diabetes mellitus	7.2e-06	9.01e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—LEP—type 2 diabetes mellitus	7.2e-06	9.01e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.12e-06	8.91e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	6.98e-06	8.74e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—INS—type 2 diabetes mellitus	6.92e-06	8.67e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—RELA—type 2 diabetes mellitus	6.89e-06	8.62e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	6.84e-06	8.56e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	6.84e-06	8.56e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.81e-06	8.53e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.79e-06	8.5e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	6.7e-06	8.39e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.7e-06	8.38e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.69e-06	8.38e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.66e-06	8.34e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	6.66e-06	8.34e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	6.66e-06	8.34e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	6.66e-06	8.34e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	6.62e-06	8.29e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	6.5e-06	8.14e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	6.43e-06	8.05e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.42e-06	8.04e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.36e-06	7.96e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.27e-06	7.85e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.21e-06	7.78e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.17e-06	7.73e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—INS—type 2 diabetes mellitus	6.15e-06	7.7e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.07e-06	7.6e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.07e-06	7.6e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.05e-06	7.58e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	5.98e-06	7.48e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	5.98e-06	7.48e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	5.98e-06	7.48e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.95e-06	7.45e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.94e-06	7.44e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.92e-06	7.41e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.87e-06	7.35e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	5.87e-06	7.34e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	5.81e-06	7.28e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.81e-06	7.27e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—RELA—type 2 diabetes mellitus	5.71e-06	7.16e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.69e-06	7.13e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	5.69e-06	7.12e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.65e-06	7.07e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	5.47e-06	6.84e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—SRC—type 2 diabetes mellitus	5.41e-06	6.78e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	5.4e-06	6.77e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	5.4e-06	6.77e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.39e-06	6.75e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.39e-06	6.75e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.27e-06	6.6e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.2e-06	6.51e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	5.18e-06	6.49e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	5.18e-06	6.49e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.15e-06	6.45e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.12e-06	6.41e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	5.08e-06	6.36e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.87e-06	6.1e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.84e-06	6.06e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.82e-06	6.03e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.74e-06	5.94e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.72e-06	5.92e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.62e-06	5.79e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.58e-06	5.73e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.55e-06	5.7e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—SRC—type 2 diabetes mellitus	4.49e-06	5.62e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.47e-06	5.59e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	4.47e-06	5.59e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	4.44e-06	5.57e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	4.39e-06	5.49e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.37e-06	5.48e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.33e-06	5.42e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.28e-06	5.36e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	4.26e-06	5.33e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.2e-06	5.25e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	4.14e-06	5.19e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	4.07e-06	5.09e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.01e-06	5.03e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	3.99e-06	4.99e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	3.98e-06	4.98e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	3.97e-06	4.97e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.94e-06	4.93e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.89e-06	4.86e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	3.86e-06	4.84e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	3.81e-06	4.78e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	3.66e-06	4.58e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IL6—type 2 diabetes mellitus	3.64e-06	4.56e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	3.59e-06	4.5e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.57e-06	4.47e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.5e-06	4.38e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	3.48e-06	4.35e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	3.42e-06	4.28e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	3.41e-06	4.27e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	3.37e-06	4.22e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.36e-06	4.21e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL6—type 2 diabetes mellitus	3.03e-06	3.79e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	2.97e-06	3.72e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	2.91e-06	3.65e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.79e-06	3.49e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.69e-06	3.36e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.67e-06	3.34e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	2.55e-06	3.2e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	2.55e-06	3.2e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.48e-06	3.1e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.33e-06	2.92e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.17e-06	1.47e-05	CbGpPWpGaD
